Health Care Distributors

Cosmos Health

Cosmos Health released FY2025 Q4 earnings on April 15 (EST), actual revenue USD 19.7 M (forecast USD 18.82 M), actual EPS USD -0.2843 (forecast USD -0.04)

Cosmos Health released FY2025 Annual Earnings on April 15 (EST), actual revenue USD 65.27 M (forecast USD 64.4 M), actual EPS USD -0.632 (forecast USD -0.34)

Cosmos Health Inc. Plans to Expand US Market Through Collaboration with DolCas Biotech

Cosmos Health released FY2025 9 Months Earnings on November 14 (EST), actual revenue USD 45.57 M, actual EPS USD -0.3062

Cosmos Health released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 17.11 M (forecast USD 16.4 M), actual EPS USD -0.1747 (forecast USD -0.01)

Cosmos Health Inc. Purchases Additional $300,000 in Ethereum

Cosmos Health released FY2025 Q2 earnings on August 18 (EST), actual revenue USD 14.75 M (forecast USD 17.48 M), actual EPS USD -0.0999 (forecast USD 0.01)

Cosmos Health released FY2025 Semi-Annual earnings on August 18 (EST), actual revenue USD 28.46 M, actual EPS USD -0.133

Cosmos Health Secures $300 Million Financing for Ethereum Reserve

Cosmos Health Enters US Market Through Manufacturing Agreement with DolCas Biotech

Cosmos Health Inc. CEO Reports Acquisition of Common Stock

Cosmos Health Inc. CEO Buys Company Shares

Cosmos Health released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 13.71 M (forecast USD 15.5 M), actual EPS USD -0.0314 (forecast USD -0.03)

Cosmos Health Granted 180-Day Extension by NASDAQ to Meet Bid Price Requirements

Cosmos Health Granted Extra Time to Meet NASDAQ Listing Standards

Cosmos Health CEO Increases Stock Holdings

Cosmos Health CEO Acquires Common Stock

Cosmos Health CEO Acquires Shares Through Debt Exchange Agreement

Cosmos Health released FY2024 annual earnings on April 15 (EST), actual revenue USD 54.43 M (forecast USD 54.7 M), actual EPS USD -1.1699 (forecast USD -0.78)

Cosmos Health released FY2024 Q4 earnings on April 15 (EST), actual revenue USD 14.22 M (forecast USD 14.5 M), actual EPS USD -0.4117 (forecast USD -0.09)

Liminatus Pharma

Agape ATP

Sunshine Biopharma

NewGenIvf

Co-Diagnostics

AIAI

Tradr 2X Long QBTS Daily ETF

Tradr 2X Long RGTI Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Wheeler Real Estate

COSM

Cosmos Health reported a Q1 FY26 net loss of $2.81 million, an increase attributed to non-cash items, despite a 30.7% rise in revenue to $17.93 million. Total liabilities decreased by 9.6% to $42.54 million, while stockholders’ equity rose by 7.6% to $19.83 million. The company is expanding into the U.S. nutraceuticals market.

PUBT

ACCESS Newswire

Cosmos Health Q1 FY26 net loss widens to $2.81 million; revenue rises 30.7% to $17.93 million

Cosmos Health Inc. reported a 30.7% revenue increase to $17.93M in Q1 2026, despite a net loss of $2.81M and a diluted EPS of ($0.06). Growth was driven by subsidiaries and a shift towards wholesale distribution. Strategic initiatives include M&A activity and international expansion, particularly in the UAE, Cyprus, and Greece.

TradingView

SPDR Pharmac

VG Health

iShares Global Healthcare

Health Care Select Sector SPDR

Cosmos Health Inc. 1Q 2026: Revenue $17.93M, EPS ($0.06) — 10-Q Summary

COSM (Cosmos Health Inc.) will announce its Q1'26 results on May 20 at 8:00 AM ET. The revenue estimate is $21.67 million, with an anticipated EPS of (0.01) USD. Previous quarters showed revenue surprises of +4.33% and +4.68%. EPS reported for Q1'25 and Q2'25 were (0.53) and (0.33) respectively, with significant EPS surprises noted.

Factset Research

COSM Q1'26 Earnings: EPS estimate is (0.01) USD

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1 | COSM Stock News

StockTitan

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1 | COSM Stock News

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months | COSM Stock News

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months | COSM Stock News

Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness | COSM Stock News

Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness | COSM Stock News

ARKG

LABU

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months | COSM Stock News

iShares US Medical Devices

VanEck Pharmaceutical ETF

iShares Biotechnology ETF

VanEck Biotech ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

iShares US Pharma

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months | COSM Stock News

SNES

CMPX

GOSS

SBIO

In Friday's after-market session, several health care stocks experienced notable movements. Intellia Therapeutics (NTLA) surged 19.1% to $16.23, while Compass Therapeutics (CMPX) rose 12.32% to $5.65. Other gainers included CDT Equity (up 9.09%), GT Biopharma (up 8.8%), SenesTech (up 8.49%), and Gossamer Bio (up 6.14%). Conversely, Armata Pharmaceuticals (ARMP) fell 9.1% to $11.75, followed by iTonic Holdings (down 8.51%) and Cosmos Health (down 7.3%).

Cosmos Health(COSM.US)

Cosmos Health Q1 FY26 net loss widens to $2.81 million; revenue rises 30.7% to $17.93 million

Cosmos Health Inc. 1Q 2026: Revenue $17.93M, EPS ($0.06) — 10-Q Summary

COSM Q1'26 Earnings: EPS estimate is (0.01) USD

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1 | COSM Stock News

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months | COSM Stock News

Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness | COSM Stock News

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months | COSM Stock News

12 Health Care Stocks Moving In Friday's After-Market Session